Skip to main content

Table 2 Changes in REVEAL risk score at ≥6-month time point: overall and by time since diagnosis and PAH therapy

From: Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study

 Baseline score, mean (SD)≥6-month score, mean (SD)Mean change (95% CI)p-value
Total (n = 57)8.7 (2.4)7.2 (2.4)−1.4 (−2.0, −0.9)< 0.0001
 Macitentan monotherapy (n = 25)7.8 (2.2)6.5 (2.4)−1.2 (− 2.0, − 0.5)0.0050
 Macitentan + PDE5 inhibitor (n = 25)9.5 (2.3)7.9 (2.5)−1.6 (−2.7, − 0.5)0.0070
 Macitentan + prostacyclin / Macitentan + PDE5 inhibitor + prostacyclin (n = 7)8.9 (2.3)7.4 (2.2)−1.4 (−2.7, −0.1)0.0308
Incident (n = 23)8.9 (2.7)7.0 (2.3)−1.8 (−3.0, −0.7)0.0040
 Macitentan monotherapy (n = 15)7.9 (2.2)6.6 (2.2)−1.3 (−2.5, − 0.2)0.0300
 Macitentan + PDE5 inhibitor (n = 8)10.6 (2.7)7.9 (2.4)−2.8 (−5.8, − 0.3)0.0650
Prevalent (n = 34)8.5 (2.2)7.4 (2.6)−1.2 (− 1.8, −0.5)0.0010
 Macitentan monotherapy (n = 10)7.5 (2.3)6.4 (2.8)−1.1 (−2.2, 0.04)0.0707
 Macitentan + PDE5 inhibitor (n = 17)9.0 (2.0)8.0 (2.6)−1.1 (−2.1, −0.04)0.0516
 Macitentan + prostacyclin / Macitentan + PDE5 inhibitor + prostacyclin (n = 7)8.9 (2.3)7.4 (2.2)−1.4 (−2.7, −0.1)0.0308
  1. Significant p-values are marked in bold
  2. CI confidence interval, PDE5 phosphodiesterase type 5, SD standard deviation